Analytical Data
-
Gene name
TRAC
- Application
-
Alternative Names
TRAC；TCRA；T cell receptor alpha chain constant
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P01848
-
Expression Region
1-142aa
-
AA Sequence
PNIQNPDPAVYQLRDSKSSDKSVCLFTDFDSQTNVSQSKDSDVYITDKTVLDMRSMDFKSNSAVAWSNKSDFACANAFNNSIIPEDTFFPSPESSCDVKLVEKSFETDTNLNFQNLSVIGFRILLLKVAGFNLLMTLRLWSS
-
Molecular Weight
17.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TRAC (T cell receptor-derived adoptive cell therapy) is an innovative approach in the field of immunotherapy, focusing on harnessing the power of the immune system to combat cancers and other diseases. The background of TRAC research lies in the ability of T-cell receptors (TCRs) to recognize and bind to specific antigens presented by cancer cells, thereby activating T cells to target and destroy malignant cells. Traditional methods of T cell engineering often face challenges in specificity and persistence, leading to suboptimal therapeutic outcomes. TRAC technology aims to address these issues by reformatting and enhancing TCRs, allowing for more effective recognition of cancer antigens. This research has gained momentum due to the increasing incidence of cancer worldwide and a growing understanding of the immune system's role in tumor surveillance. By optimizing TRAC proteins, scientists aim to improve the safety and efficacy of T cell therapies, thus paving the way for personalized treatment strategies that can adapt to individual patient needs. Ongoing studies are exploring various aspects of TRAC protein structure, functionality, and clinical applications, with the objective of developing next-generation immunotherapies that can ultimately transform cancer treatment paradigms.
